Veozah vs Orilissa
A side-by-side look at two women's health medications advertised on TV. Informational only — not medical advice.
| US Veozah | US Orilissa | |
|---|---|---|
| Generic name | fezolinetant | elagolix |
| Drug class | NK3 Receptor Antagonist | GnRH Antagonist |
| Treats | Menopausal hot flashes | Endometriosis pain |
| Category | Women's Health | Women's Health |
| Manufacturer | Astellas Pharma | AbbVie |
| Year approved | 2023 | 2018 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $110M | $60M |
| Common side effects | Liver injury risk, Abdominal pain, Diarrhea, Insomnia | Hot flashes, Headache, Nausea, Bone density loss |
Frequently asked questions
Is Veozah or Orilissa better?
Neither is universally "better." Veozah (fezolinetant) and Orilissa (elagolix) are both used for women's health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Veozah and Orilissa?
Veozah is a NK3 Receptor Antagonist made by Astellas Pharma, while Orilissa is a GnRH Antagonist made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Veozah has the larger estimated TV advertising budget of the two.